Aspirin’s echo: rebound, delay, or statistical mirage? Re-examining legacy cardiovascular risk after cessation

European Heart Journal

18 November 2025
Organised by: Logo
ESC Journals CARDIOVASCULAR DISEASE IN SPECIFIC POPULATIONS CARDIOVASCULAR PHARMACOLOGY

ESC 365 is supported by